Migraine is a neurovascular disorder that can be debilitating for individuals and society.
Current research focuses on finding effective analgesics and management strategies for …

Migraine is a debilitating disease that affects almost 15% of the population worldwide and is
the first cause of disability in people under 50 years of age, yet its etiology and …

Introduction Interest is growing in the role of pituitary adenylate cyclase-activating
polypeptide (PACAP) and its specific PAC1 receptor in migraine and in their antagonism as …

The neuropeptides calcitonin gene-related peptide (CGRP) and pituitary adenylate cyclase-
activating polypeptide (PACAP) have emerged as mediators of migraine pathogenesis. Both …

Background Migraine is a disabling and chronic neurovascular headache disorder.
Trigeminal vascular activation and release of calcitonin gene-related peptide (CGRP) play a …

Here, we review the role of pituitary adenylate cyclase-activating peptide-38 (PACAP38) in
migraine pathophysiology and data implicating PAC 1 receptor as a future drug target in …

Migraine is a widespread and debilitating neurological condition affecting more than a
billion people worldwide. Thus, more effective migraine therapies are highly needed. In the …

Calcitonin gene-related peptide (CGRP)-antagonizing drugs represent a major advance in
migraine treatment. However, up to 50% of patients do not benefit from monoclonal …

Background Targeting pituitary adenylate cyclase–activating polypeptide (PACAP) is a new
avenue for treating migraine. The efficacy and safety of intravenous Lu AG09222, a …

Pituitary adenylate cyclase activating polypeptide-38 (PACAP38) is a widely distributed
neuropeptide involved in neuroprotection, neurodevelopment, nociception and …